Evidence map›Paper›PMID 41661076›Full record

ArticleCancer discovery2026

Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression.

Jérémy Nigri, Wenjun Lan, Melanie L Fung, Charlotte Kayser, Astrid Deschênes, Juliene Hinds, Sanjeev Kaushalya, Sara A Pawlak, Jennifer S Thalappillil, Sandeep Nadella and 10 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jérémy NigriCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0003-1358-1863
Wenjun LanCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0001-7124-7471
Melanie L FungCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0009-0007-4366-5909
Charlotte KayserCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0009-0004-2987-8471
Astrid DeschênesCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0001-7846-6749
Juliene HindsCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0009-0006-8576-9856
Sanjeev KaushalyaCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-3469-2637
Sara A PawlakCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0009-0005-0322-0628
Jennifer S ThalappillilCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-4860-3033
Sandeep NadellaCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-3290-4018
Marc HilmiDavid M. Rubenstein Center for Pancreatic Cancer Research, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4762-6740
Wungki ParkDavid M. Rubenstein Center for Pancreatic Cancer Research, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8006-3102
Rajya KappagantulaDavid M. Rubenstein Center for Pancreatic Cancer Research, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0009-0292-7882
Youngkyu ParkCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0003-1169-6739
Zhen ZhaoCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0001-5271-4759
Jonathan PreallCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-7772-2437
Christine A Iacobuzio-DonahueDavid M. Rubenstein Center for Pancreatic Cancer Research, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4672-3023
Kevin J TraceyFeinstein Institutes at Northwell Health, Manhasset, New York.ORCID 0000-0003-1884-6314
Jeremy C BornigerCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-5419-0271
David A TuvesonCold Spring Harbor Laboratory , Cold Spring Harbor, New York.ORCID 0000-0002-8017-2712

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI David A Tuveson · 1987 to 2026
$118.9M
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christine A Iacobuzio-Donahue · 2022 to 2026
$14.3M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
Molecular Basis of Bioelectronic MedicineR35GM118182 · NIGMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI TRACEY, KEVIN J · 2016 to 2025
$7.3M
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor HeterogeneityU01CA224013 · NCI · COLD SPRING HARBOR LABORATORY · PI ROBSON, PAUL, TUVESON, DAVID A · 2018 to 2022
$4.2M
Fibroblast Heterogeneity in Pancreatic CancerR01CA249002 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2021 to 2025
$3.9M
Central mechanisms of glucocorticoid circadian rhythm dysfunction in breast cancerR01CA286651 · NCI · COLD SPRING HARBOR LABORATORY · PI Jeremy Borniger · 2024 to 2026
$2.3M
Preclinical Models for Cancer Therapeutic DevelopmentR50CA211506 · NCI · COLD SPRING HARBOR LABORATORY · PI PARK, YOUNGKYU · 2016 to 2025
$2.1M
SOAT1 as a targetable dependency in Pancreatic AdenocarcinomaR01CA292775 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses, David A Tuveson · 2025 to 2026
$1.6M
Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic CancerUG3CA290364 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses, David A Tuveson · 2025 to 2026
$797k
Cold Spring Harbor Laboratory (CSHL)Lustgarten Foundation (Lustgarten)National Cancer Institute (NCI) 1R01CA249002National Cancer Institute (NCI) 5P30CA045508National Cancer Institute (NCI) F31CA247416National Cancer Institute (NCI) R01CA286651National Institute of General Medical Sciences (NIGMS) R35GM118182National Institutes of Health (NIH) 1UG3CA290364National Institutes of Health (NIH) R01CA292775National Institutes of Health (NIH) R50CA211506National Institutes of Health (NIH) S10OD028632National Institutes of Health (NIH) U01CA210240National Institutes of Health (NIH) U01CA224013NCI NIH HHS F31 CA247416NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA045508NCI NIH HHS P50 CA257881NCI NIH HHS R01 CA249002NCI NIH HHS R01 CA286651NCI NIH HHS R01 CA292775NCI NIH HHS R50 CA211506NCI NIH HHS U01 CA210240NCI NIH HHS U01 CA224013NCI NIH HHS UG3 CA290364NIGMS NIH HHS R35 GM118182NIH HHS S10 OD028632Pancreatic Cancer Action Network (PCAN) 25-MF-NIGRPershing Square Foundation (PSF)Thompson Foundation (The Thompson Foundation)U.S. Department of Defense (DOD) HT9425-25-1-0434
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) co-opts the peripheral nervous system through nerve hypertrophy, axonogenesis, and perineural invasion, and these processes correlate with patient morbidity and mortality. Prior work has shown that autonomic nerves directly modulate neoplastic cells in PDAC, but whether cancer-associated fibroblasts (CAF) participate in neural remodeling is unknown. Using thick tissue sections, we identified dense neo-innervation near myofibroblastic CAFs (myCAF) in preinvasive pancreatic intraepithelial neoplasms. Mechanistically, TGFβ produced during inflammation and neoplasia triggers myofibroblast formation, and myCAFs produce axon guidance molecules that recruit sympathetic nerves. Norepinephrine released by sympathetic nerves activates myofibroblast cultures in vitro, and sympathetic nerve depletion impairs stromal activation and PDAC growth in vivo. A chemogenetic model confirmed that fibroblast-specific α1-adrenergic signaling exacerbated pancreatic inflammation and neoplasia. Therefore, beyond direct epithelial effects, sympathetic nerves promote pancreatitis and PDAC by co-opting myofibroblasts and myCAFs as disease amplifiers, highlighting CAF subtype-specific stromal interactions as putative therapeutic targets. SIGNIFICANCE: Pathology-associated myofibroblasts orchestrate bidirectional cross-talk with sympathetic neurons, secreting axon guidance molecules to promote nerve infiltration in inflamed and neoplastic pancreatic tissues. Specifically, α1-adrenoreceptor activation in fibroblasts acts as a molecular switch that amplifies pancreatitis severity and accelerates tumor growth, revealing new paracrine and juxtacrine interactions for further therapeutic development. See related commentary by Hondermarck et al., p.834.

Indexed as

Carcinoma, Pancreatic DuctalMyofibroblastsNeuronal PlasticityPancreatic NeoplasmsPancreatitisAnimalsCancer-Associated FibroblastsDisease ProgressionHumansInflammationMice

Identifiers

PMID41661076
PMCPMC13102267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.